Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model

Filiaciones

Fenaux P:

Hôpital St Louis, Paris 7 University, Paris, France.

Seymour JF:

Peter MacCallum Cancer Centre, East Melbourne, & University of Melbourne, Australia

Santini V:

University of Florence, Florence, Italy

Silverman L:

Mount Sinai School of Medicine, New York, NY, USA

Gore S:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

List A:

H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Sanz G:

Hospital Universitario y Politécnico La Fe, Valencia, Spain

Mufti GJ:

King's College London, London, UK

Estey E:

Division of Hematology, University of Washington School of Medicine, Seattle, WA, USA

Swern AS:

Celgene Corporation, Summit, NJ, USA

Beach CL:

Celgene Corporation, Summit, NJ, USA

Hellstrom-Lindberg E:

Karolinska Institute, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden